Avadel Pharmaceuticals Q2 2023 Earnings Report $7.75 -0.25 (-3.13%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Avadel Pharmaceuticals EPS ResultsActual EPS-$0.70Consensus EPS -$0.39Beat/MissMissed by -$0.31One Year Ago EPSN/AAvadel Pharmaceuticals Revenue ResultsActual Revenue$1.50 millionExpected Revenue$1.27 millionBeat/MissBeat by +$230.00 thousandYoY Revenue GrowthN/AAvadel Pharmaceuticals Announcement DetailsQuarterQ2 2023Date8/9/2023TimeN/AConference Call ResourcesPress ReleaseAVDL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Avadel Pharmaceuticals Earnings HeadlinesAvadel Pharmaceuticals (NASDAQ:AVDL) Price Target Lowered to $14.00 at UBS GroupJanuary 15 at 3:27 AM | americanbankingnews.comLifesci Capital Has Pessimistic View of AVDL FY2024 EarningsJanuary 14, 2025 | americanbankingnews.comTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market. But hurry... After January 20th, it could be too late.January 18, 2025 | InvestorPlace (Ad)Avadel Pharmaceuticals price target lowered to $14 from $22 at UBSJanuary 14, 2025 | markets.businessinsider.com3 Oversold Biotech NamesJanuary 13, 2025 | seekingalpha.comAvadel Pharmaceuticals (NASDAQ:AVDL) Given New $13.00 Price Target at Piper SandlerJanuary 13, 2025 | americanbankingnews.comSee More Avadel Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avadel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avadel Pharmaceuticals and other key companies, straight to your email. Email Address About Avadel PharmaceuticalsAvadel Pharmaceuticals (NASDAQ:AVDL) operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.View Avadel Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
